ArticleFrontiers in molecular biosciences2026
SM-GAT: a safety-aware multi-task graph attention network for multi-target anti-diabetic lead discovery from natural products.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional Chinese Medicine constitutes a chemically diverse and pharmacologically rich reservoir of bioactive compounds, often exhibiting multi-target pharmacological properties that are potentially valuable for complex metabolic disorders such as type 2 diabetes mellitus (T2DM). However, systematic prioritization of active and safe constituents remains challenging, as therapeutic efficacy must be optimized concurrently with toxicity risk. Here, we present a safety-aware Multi-Task Graph Attention Network (SM-GAT) framework that jointly models anti-diabetic efficacy and toxicity liabilities of TCM-derived compounds within a unified architecture. Four tasks are simultaneously optimized: inhibition of dipeptidyl peptidase-4 (DPP4), inhibition of α-glucosidase, acute oral toxicity, and clinically relevant toxicity. By enabling shared molecular representation learning across heterogeneous yet biologically related endpoints, SM-GAT facilitates knowledge transfer between efficacy and safety domains. Across all prediction tasks, SM-GAT achieved competitive or superior performance compared with single-task graph neural networks and other baseline models, achieving ROC-AUC values up to 0.892 for α-glucosidase inhibition. Notably, multi-task learning yields pronounced improvements in data-limited settings, highlighting effective cross-task regularization. Large-scale virtual screening of the TCMBank library demonstrates practical applicability, enabling efficient prioritization of structurally diverse candidates with favorable predicted efficacy-safety balance. Several structurally diverse lead compounds, including ellagic acid derivatives, are identified with favorable predicted efficacy-safety balance. Furthermore, atom-level attention analysis highlighted chemically interpretable substructures associated with predicted efficacy and toxicity-related molecular representations. Collectively, this study establishes an interpretable multi-objective framework for safety-aware lead discovery, providing a computational framework for integrating traditional botanical resources into anti-diabetic lead discovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.